Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

PR Newswire July 27, 2023

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

PR Newswire June 14, 2023

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

PR Newswire June 7, 2023

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

PR Newswire May 16, 2023

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

PR Newswire May 11, 2023

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

PR Newswire April 3, 2023

Lipocine Announces Financial Results for the Year Ended December 31, 2022

PR Newswire March 10, 2023

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

PR Newswire March 10, 2023

Lipocine to Present at Biotech Showcase

PR Newswire January 5, 2023

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

PR Newswire December 19, 2022

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

PR Newswire November 9, 2022

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

PR Newswire November 3, 2022

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference

PR Newswire October 11, 2022

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

PR Newswire September 27, 2022

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

PR Newswire September 26, 2022

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

PR Newswire September 22, 2022

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

PR Newswire September 15, 2022

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

PR Newswire August 8, 2022

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

PR Newswire July 11, 2022

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

PR Newswire June 14, 2022